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response. This elegant series of experi-
ments by Saijo and colleagueswill change
this view and hopefully accelerate our
understanding of the roles of ERb in MS
and, possibly, in autoimmune diseases
more generally, including how gender
affects their development.
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Hormonal regulation of glucose and lipid metabolism is pivotal for metabolic homeostasis and
energy balance. Two studies in this issue ofCell (Mihaylova et al., 2011 andWang et al., 2011) intro-
duce a new conserved signaling mechanism controlling catabolic gene expression: class IIa
histone deacetylases (HDACs) regulate Foxo activity in Drosophila and mice.The hormones insulin and glucagon
are central to regulating glucose homeo-
stasis in vertebrates (Biddinger and Kahn,
2006). During states of fasting, glucagon
initiates the production of glucose (i.e.,
gluconeogenesis) in the liver by increasing
the transcription of gluconeogenic en-
zymes, such as glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate car-
boxykinase (PEPCK). When nutrients are
increased, insulin then attenuates gluco-
neogenesis in the liver and initiates
glucoseuptake inperipheral tissues, stabi-
lizing blood glucose concentrations while
also promoting anabolic processes and
energy storage. When this regulation of
glucose homeostasis dysfunctions, meta-
bolic disorders develop, such as type 2
diabetes and metabolic syndrome. Thus,
deciphering the details of this signaling
network promises to provide new strate-
gies for treating these diseases. Now two
studies in this issue of Cell take the firststep toward bringing this promise to
fruition; they uncover a pivotal role for
histone deacetylases in glucose homeo-
stasis, suggesting that established HDAC
inhibitors may be effective at mitigating
diabetes and metabolic syndrome.
In the liver, glucagon stimulates tran-
scription of gluconeogenic genes through
a signaling pathway (Figure 1, left) that
includes the cAMP-dependent Protein
Kinase A (PKA) and the AMP-dependent
protein kinase family members AMPK
(AMP-activated protein kinase), SIK1
(salt-inducible kinase 1), and SIK2 (Viollet
et al., 2009). AMPK and its upstream
kinase LKB1 (Liver Kinase 1) inhibit gluco-
neogenic gene transcription in hepatic
cells by suppressing nuclear transloca-
tion of the transcriptional coactivator
CRTC2 (CREB-regulated transcription
coactivator 2)/TORC2. Once PKA blocks
AMPK and SIK1/2, CRTC2 associates
with the transcription factor CREB toinduce the coactivator PGC-1a (peroxi-
some proliferator-activated receptor
gamma coactivator-1 alpha), which in
turn associates with the transcription
factors Foxo1 (Forkhead box o1) and
HNF4a (hepatocyte nuclear factor 4
alpha) to activate gluconeogenic gene
expression (Altarejos and Montminy,
2011; Viollet et al., 2009).
Insulin attenuates glucose production
by influencing the samepathway (Figure1,
left). Activation of the insulin-responsive
Akt kinase results in the inhibition of
CRTC2 via SIK1/2, as well as phosphory-
lation and inactivation of Foxo (Viollet
et al., 2009).
In addition to this hormone-mediated
control of glucose metabolism, the cell’s
energy balance also influences glucose
production through a family of class III
histone deacetylases (HDACs), called
Sirtuins, which couple deacetylation with
NAD (nicotinamide adenine dinucleotide)145, May 13, 2011 ª2011 Elsevier Inc. 497
Figure 1. Model for How Type IIa HDACs Regulate Foxo in Drosophila and Mice
Left: In vertebrates, insulin and glucagon control glucose homeostasis by differentially regulating a well-
characterized pathway that involves the cAMP-dependent Protein Kinase A (PKA), AMP-activated protein
kinase (AMPK), SIK1/2 (salt-inducible kinase 1/2), and the Akt kinase. This signaling cascade ultimately
leads to the regulation of the Forkhead box o (Foxo) transcription factors, which control transcription of
gluconeogenic genes. Mihaylova et al. (2011) find that class IIa histone deacetylases (HDACs) also control
gluconeogenic gene expression in mouse hepatocytes by regulating the acetylation state of Foxo.
Right: In invertebrates, glucose homeostasis is also regulated by insulin- and glucagon-like hormones,
such as the Drosophila insulin-like peptides (dILPs) and the adipokinetic hormone (AKH). Wang et al.
(2011) find that, in Drosophila, class IIa HDACs also regulate Foxo acetylation and ultimately gluconeo-
genic gene expression in the fly’s fat body. The fat body is the fly equivalent of the mammalian adipose
tissue, but it also has functions similar to those of the liver.hydrolysis and, thus, are sensitive to
the cellular NAD:NADH ratio. These
factors control the activity of a variety of
transcription factors, including Foxo1.
Previous studies have established that
acetylation of Foxo modulates both its
promoter specificity and transcriptional
activity, which in turn influences metabo-
lism, cell proliferation, and survival (Guar-
ente, 2006; Haigis and Sinclair, 2010).
Disrupting SIRT1 expression in the liver
of mice reduces gluconeogenesis and
fatty acid beta-oxidation, highlighting
the importance of Sirtuins in metabolic
regulation. However, the ultimate conse-
quence of losing SIRT1 on glucose
homeostasis remains controversial (Puru-
shothamet al., 2009;Rodgers et al., 2008).
The findings reported by Mihaylova
et al. and Wang et al. now implicate498 Cell 145, May 13, 2011 ª2011 Elsevier Ina second class of HDACs—the class IIa
HDACs—in the regulation of Foxo during
glucose and lipid metabolism in both
mammals and the fruitfly Drosophila
melanogaster. Strikingly, they find that
the LKB/SIK1/2/AMPK module directly
regulates these HDACs (Figure 1),
activating Foxo to promote gluconeo-
genic gene expression in response to
glucagon.
Using a combination of genetic and
biochemical approaches, Mihaylova and
colleagues find that deleting LKB1 in the
mouse liver blocks basal phosphorylation
of several class IIa HDACs: HDAC4,
HDAC5, and HDAC7. Furthermore,
injecting mice with metformin, an AMPK/
LKB1 agonist, increases phosphorylation
of HDACs 4/5/7 in the liver and promotes
their retention in the cytoplasm. In res-c.ponse to fasting or glucagon treatment,
these HDACs are dephosphorylated and
accumulate in the nucleus of hepato-
cytes, where they act as scaffolds for
the class I HDAC3. HDAC3 is catalytically
active, and inside the nucleus it activates
Foxo1 by deacetylation, ultimately
leading to gluconeogenic gene expres-
sion (Figure 1, left).
Using Drosophila genetics, Wang and
colleagues add one more step to this
pathway; they identify an evolutionarily
conserved role of SIK3, the fly homolog
of mammalian SIK2. They find that SIK3
phosphorylates and inhibits HDAC4
during feeding states. As in mammals,
the translocation of HDAC4 into the
nucleus leads to Foxo deacetylation
and activation of catabolic enzymes,
including phosphoenolpyruvate carboxy-
kinase (PEPCK) and the brummer (bmm)
lipase, the fly homolog of adipose triglyc-
eride lipase (ATGL).
Previous studies have reported that the
SIK kinase regulates HDACs in mouse
skeletal myocytes (Berdeaux et al.,
2007), and now Wang and colleagues
show that this regulation is conserved in
flies. When SIK3 is mutated, HDAC4 is
activated and translocates to the nucleus,
where it subsequently switches on Foxo
(Figure 1, right). This leads to lipolysis in
the fat bodies of the mutant flies and
significantly decreases lipid stores. The
fat body is the fly equivalent of the
mammalian adipose tissue and also has
similar functions as the liver. Interestingly,
in feeding flies, AKT stimulates SIK3
activity, indicating that SIK3 might inte-
grate insulin- and glucagon-like stimuli in
the fly to adjust HDAC4 activity in
response to systemic energy require-
ments.
Thus, in both flies and mice, the regula-
tion of Foxo function through class IIa
HDACs emerges as a critical step in the
control of energy metabolism under star-
vation conditions. Indeed, Mihaylova
and colleagues directly demonstrate the
significance of these HDACs in metabolic
diseases, as reducing HDAC 4/5/7
expression in the liver by RNA interfer-
ence strikingly improves glucose toler-
ance in several mouse models of
metabolic diseases, including hypergly-
cemia induced by a high-fat diet and
genetic models of obesity. This mecha-
nism thus presents a unique opportunity
to develop class II HDAC inhibitors as
therapeutics for treating metabolic disor-
ders. Given that pharmacological HDAC
inhibitors are already in development as
potential anticancer agents, this strategy
seems particularly promising.
Importantly, the two new studies also
raise a number of complex questions
that are critical to understanding the regu-
lation of metabolic homeostasis. First, the
studies highlight the importance of acety-
lation in controlling Foxo function. Given
Foxo’s involvement in numerous physio-
logical processes, this regulatory mecha-
nism is expected to influence not only
metabolism but also cell growth, prolifera-
tion, apoptosis, and longevity. However,
the relative contributions of Sirtuins and
class IIa HDACs for controlling Foxo
activity still remain unknown. It will also
be important to understand why gluco-
neogenic gene expression is regulated
by two distinct pathways: HDAC inhibitionby AMPK/SIK1/2 and CRTC2 inhibition by
SIK1/2. One speculation is that the per-
ceived redundancy allows intricate, con-
text-dependent regulation of gluconeo-
genesis or of Foxo function more
generally. Finally, the physiologic conse-
quences of this regulatory mechanism
might reach beyond glucose and lipid
homeostasis and may include Foxo-
mediated control of life span, cell survival,
and growth. The combined power of
Drosophila and mouse genetics will
clearly provide key insights into these
intriguing questions.REFERENCES
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Bridging a gap between transcriptomics and the study of cis-acting elements (cistromics), Hah et al.
(2011) apply a next-generation sequencing technique to gain an unprecedented view of the
changes in RNA synthesis that occur following estrogen receptor activation in human breast cancer
cells.The regulation of eukaryotic gene expres-
sion is remarkably complex, with the tran-
scriptome in any given cell affected by the
epigenome, which is acted upon by tran-
scription factors binding to cis-acting
elements (the cistrome) and RNA poly-
merases that generate messenger RNAs
(mRNAs) (Figure 1). In this issue, Hah
et al. (2011) bridge transcriptomics and
cistromics to provide surprising insightsinto the genome-wide distribution and
dynamics of transcription in response to
an external stimulus—in this case, the
exposure of human breast cancer cells
to the hormone estrogen.
Techniques based on next-generation
sequencing, most notably chromatin
immunoprecipitation sequencing (ChIP-
seq) andRNA-seq are greatly contributing
to our understanding of transcriptionalregulation. ChIP-seq enables researchers
to localize transcription factor binding or
specific nucleosome structures defining
cistromes in a given cell type or tissue
under different conditions (Lupien and
Brown, 2009). RNA-seq makes it possible
to assay many species of transcripts,
including mRNAs, noncoding RNAs, and
small RNAs, while providing exact infor-
mation about alternative splice variants145, May 13, 2011 ª2011 Elsevier Inc. 499
